Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Digestion. 2013;88(1):17-9. doi: 10.1159/000351386. Epub 2013 Jun 20.
It is not too much to say that infliximab has revolutionized the treatment of Crohn's disease. However, there is the problem of 'secondary failure' wherein the effect may diminish during treatment. This is a much-discussed topic. For example, not all patients with secondary failure can maintain remission with dose intensification to 10 mg/kg. It is also important to make the appropriate drug selection and to clarify the optimal timing of dose intensification for achieving long-term maintenance of remission, including discussion of the first priority use of adalimumab.
可以毫不夸张地说，英夫利昔单抗彻底改变了克罗恩病的治疗方法。然而，存在“继发性失效”的问题，即在治疗过程中疗效可能会减弱。这是一个讨论较多的话题。例如，并非所有继发性失效的患者都可以通过将剂量增加至 10mg/kg 来维持缓解。选择合适的药物也很重要，并明确实现长期缓解的最佳剂量强化时机，包括讨论阿达木单抗的优先使用。
